sFlt-1/PlGF比值预测疑似子痫前期患者分娩时机的准确性
本研究为单中心回顾性队列研究,纳入503例疑似子痫前期的单胎妊娠患者,评估Roche Elecsys sFlt-1/PlGF比值预测7天内分娩风险的能力。结果显示该比值与检测至分娩时间呈负相关,低风险比值(≤38)对7天内分娩的阴性预测值为89%,<34周时达99%。sFlt-1/PlGF比值可用于指导入院和产前糖皮质激素使用决策。
要点
- sFlt-1/PlGF≤38时,7天内分娩阴性预测值达89%,<34周时达99%。
- sFlt-1/PlGF>85时,7天内分娩阳性预测值为65%。
- 中、高风险比值与7天内分娩风险升高相关,aHR分别为1.7和5.1。
核心结论
- sFlt-1/PlGF比值是预测疑似子痫前期患者分娩时机的有效预后工具,可指导入院及产前糖皮质激素使用决策。
研究设计与样本
- 单中心回顾性队列研究,纳入2020至2023年间因疑似子痫前期行Roche Elecsys sFlt-1/PlGF比值检测的单胎妊娠患者503例。
- 采用改良Poisson回归和Cox回归生存分析评估sFlt-1/PlGF比值与7天内分娩风险的相关性。
主要发现
- 子痫前期发生率为39.8%(n=200)。
- sFlt-1/PlGF比值与检测至分娩时间呈负相关(Spearman's Rho为-0.63,置信区间为-0.73至0.63)。
- 中风险比值(>38-85)与低风险比值(≤38)相比,7天内分娩的校正风险比为1.7(95%CI 1.2-2.3)。
- 高风险比值(>85)与低风险比值(≤38)相比,7天内分娩的校正风险比为5.1(95%CI 3.8-6.9)。
- 低风险比值(≤38)对7天内分娩的阴性预测值为89%(95%CI 83%-96%),<34周时为99%(95%CI 97%-100%)。
关键数值与推荐
- sFlt-1/PlGF比值分层:低风险≤38,中风险>38-85,高风险>85。
- 高风险比值(>85)对7天内分娩的阳性预测值为65%(95%CI 56%-75%)。
- 要达到80%的阳性预测值,总体队列需sFlt-1/PlGF>365,<34周检测者需>368,≥34周检测者需>300。
临床怎么用
- 对疑似子痫前期患者,sFlt-1/PlGF≤38可用于排除短期内分娩风险,减少不必要的入院和糖皮质激素使用。
- sFlt-1/PlGF>85提示7天内分娩风险升高,可考虑积极管理,包括入院和糖皮质激素治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preeclampsia is a leading cause of maternal and fetal morbidity and mortality, but its clinical course is often difficult to predict. This can make management decisions, such as admission and administration of antenatal corticosteroids, challenging. Abnormal levels of the angiogenic proteins soluble fms-like tyrosine kinase 1 and placental growth factor have been shown to improve the diagnostic accuracy for preeclampsia. However, data on their accuracy in predicting time to delivery are limited. The objective of the present study was to fill this critical gap. STUDY DESIGN: A retrospective cohort study of patients with a singleton pregnancy in a single center evaluated for suspected preeclampsia using the Roche Elecsys soluble fms-like tyrosine kinase 1/placental growth factor ratio assay between 2020 and 2023. Modified Poisson regression and Cox regression survival analysis were used to estimate the association between the soluble fms-like tyrosine kinase 1/placental growth factor ratio and the risk of delivery within 7 days. The soluble fms-like tyrosine kinase 1/placental growth factor ratio was interpreted as low risk (≤38), moderate risk (>38-85), or high risk (>85). RESULTS: A total of 503 patients met the study criteria. The preeclampsia rate was 39.8% (n=200). The soluble fms-like tyrosine kinase 1/placental growth factor ratio was inversely associated with the testing-to-delivery time (Spearman's Rho, -0.63 [the confidence interval is -0.73 to 0.63]). Survival analysis revealed that moderate-risk and high-risk ratios were associated with shorter testing-to-delivery intervals than a low-risk ratio (adjusted hazard ratio, 1.7 [95% confidence interval, 1.2-2.3] and adjusted hazard ratio, 5.1 [95% confidence interval, 3.8-6.9], respectively). A low-risk ratio (≤38) was associated with a high negative predictive value for birth within 7 days (89% [95% confidence interval, 83%-96%]), especially when found before 34 weeks (99% [95% confidence interval, 97%-100%]). The positive predictive value of a high-risk ratio (>85) for delivery within 7 days was 65% (95% confidence interval, 56%-75%). To achieve a more clinically relevant positive predictive value of 80%, higher soluble fms-like tyrosine kinase 1/placental growth factor ratio cutoff values were required: 365 in the overall cohort, 368 in cases tested before 34 weeks, and 300 in those tested at ≥34 weeks. CONCLUSION: The soluble fms-like tyrosine kinase 1/placental growth factor ratio is a useful prognostic tool for predicting time to delivery in patients with suspected preeclampsia and can therefore guide management decisions, such as admission and the administration of antenatal corticosteroids.
引用
- Wilson, Carson, Fu, et al. The accuracy of the soluble fms-like tyrosine kinase 1/placental growth factor ratio assay in predicting time to delivery in patients with suspected preeclampsia. Am J Obstet Gynecol. 2026. PMID: 41780626. doi:10.1016/j.ajog.2026.02.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。